Prothena Sees Potential In Targeting Amyloid, Validated By Biogen

As it nears the clinic with potential Alzheimer’s disease drugs, Prothena Corporation plc will lean on the many years of experience its leadership team has in the space, including their time at Elan Corporation working on one of the first late-stage antibodies targeting amyloid-beta. The company is working on three preclinical Alzheimer’s programs now and it sees Biogen, Inc.’s aducanumab as helping to lay the groundwork for next-generation amyloid-targeting therapies, like the one in Prothena’s pipeline.

The company is conducting preclinical studies that will enable the filing of an investigational new drug (IND) application with the US Food and Drug Administration in 2021 for PRX012, an amyloid-beta-targeting antibody formulated to enable subcutaneous injection rather than I.V. dosing – the route of administration for aducanumab